title: Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy.
abstract: Considerable attention has been focused on the development of phosphonate-containing drugs for application in many therapeutic areas. However, phosphonate diacids are deprotonated at physiological pH and thus phosphonate-containing drugs are not ideal for oral administration, an extremely desirable requisite for the treatment of chronic diseases. To overcome this limitation several prodrug structures of biologically active phosphonate analogues have been developed. The rationale behind the design of such agents is to achieve temporary blockade of the free phosphonic functional group until their systemic absorption and delivery, allowing the release of the active drug only once at the target. In this paper, an overview of acyclic and cyclic nucleoside phosphonate prodrugs, designed as antiviral agents, is presented.
authors.affiliation: Welsh School of Pharmacy, Cardiff University, Cardiff, UK.
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Pertusati
authors.forename: Michaela
authors.initials: M
authors.lastname: Serpi
authors.forename: Christopher
authors.initials: C
authors.lastname: McGuigan
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008826:Microbial Sensitivity Tests; D009705:Nucleosides / Q000737:chemistry / Q000627:therapeutic use*; D063065:Organophosphonates / Q000737:chemistry*; D011355:Prodrugs / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D009705:Nucleosides; D063065:Organophosphonates; D011355:Prodrugs